Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE39.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots35.0000/ 1
- Ask / Lots62.5600/ 2
- Open / Previous Close38.4200 / 39.0400
- Day Range
- 52 Week Range
- Volume304,956
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 614 | 38.405 |
| 09:34 ET | 2400 | 38.63 |
| 09:36 ET | 200 | 38.95 |
| 09:38 ET | 100 | 38.775 |
| 09:39 ET | 300 | 38.705 |
| 09:41 ET | 100 | 38.74 |
| 09:43 ET | 100 | 38.69 |
| 09:45 ET | 300 | 38.5 |
| 09:50 ET | 658 | 38.62 |
| 09:52 ET | 400 | 38.63 |
| 09:57 ET | 100 | 38.5 |
| 10:01 ET | 100 | 38.38 |
| 10:06 ET | 200 | 38.615 |
| 10:08 ET | 100 | 38.425 |
| 10:10 ET | 300 | 38.4 |
| 10:15 ET | 100 | 38.435 |
| 10:17 ET | 100 | 38.625 |
| 10:21 ET | 600 | 38.605 |
| 10:24 ET | 200 | 38.69 |
| 10:30 ET | 809 | 38.6 |
| 10:32 ET | 547 | 38.535 |
| 10:35 ET | 246 | 38.39 |
| 10:37 ET | 100 | 38.405 |
| 10:39 ET | 636 | 38.535 |
| 10:42 ET | 300 | 38.31 |
| 10:44 ET | 300 | 38.26 |
| 10:46 ET | 500 | 38.36 |
| 10:48 ET | 130 | 38.35 |
| 10:51 ET | 100 | 38.295 |
| 10:55 ET | 100 | 38.255 |
| 10:57 ET | 200 | 38.26 |
| 11:00 ET | 200 | 38.245 |
| 11:02 ET | 429 | 38.26 |
| 11:13 ET | 100 | 38.22 |
| 11:15 ET | 200 | 38.21 |
| 11:20 ET | 900 | 38.43 |
| 11:22 ET | 100 | 38.44 |
| 11:24 ET | 200 | 38.42 |
| 11:29 ET | 200 | 38.41 |
| 11:31 ET | 100 | 38.62 |
| 11:38 ET | 100 | 38.51 |
| 11:40 ET | 100 | 38.57 |
| 11:44 ET | 200 | 38.585 |
| 11:45 ET | 744 | 38.6 |
| 11:51 ET | 715 | 38.695 |
| 11:54 ET | 1426 | 38.61 |
| 12:00 ET | 300 | 38.49 |
| 12:07 ET | 636 | 38.58 |
| 12:09 ET | 200 | 38.58 |
| 12:16 ET | 100 | 38.575 |
| 12:18 ET | 100 | 38.475 |
| 12:20 ET | 100 | 38.49 |
| 12:21 ET | 200 | 38.6 |
| 12:25 ET | 1426 | 38.54 |
| 12:34 ET | 600 | 38.38 |
| 12:36 ET | 100 | 38.29 |
| 12:38 ET | 600 | 38.255 |
| 12:39 ET | 100 | 38.2575 |
| 12:41 ET | 1533 | 38.2901 |
| 12:50 ET | 300 | 38.27 |
| 12:56 ET | 200 | 38.275 |
| 12:59 ET | 966 | 38.17 |
| 01:01 ET | 900 | 38.12 |
| 01:03 ET | 946 | 38.23 |
| 01:06 ET | 200 | 38.235 |
| 01:08 ET | 300 | 38.33 |
| 01:10 ET | 100 | 38.305 |
| 01:12 ET | 300 | 38.315 |
| 01:14 ET | 1500 | 38.355 |
| 01:15 ET | 200 | 38.37 |
| 01:17 ET | 100 | 38.325 |
| 01:19 ET | 100 | 38.45 |
| 01:21 ET | 307 | 38.47 |
| 01:24 ET | 700 | 38.48 |
| 01:26 ET | 800 | 38.47 |
| 01:28 ET | 312 | 38.66 |
| 01:30 ET | 4217 | 38.65 |
| 01:33 ET | 679 | 38.655 |
| 01:35 ET | 200 | 38.725 |
| 01:37 ET | 1709 | 38.66 |
| 01:39 ET | 1400 | 38.565 |
| 01:42 ET | 1075 | 38.65 |
| 01:46 ET | 200 | 38.685 |
| 01:50 ET | 200 | 38.72 |
| 01:51 ET | 200 | 38.72 |
| 01:53 ET | 300 | 38.67 |
| 01:55 ET | 1974 | 38.715 |
| 01:57 ET | 200 | 38.79 |
| 02:00 ET | 100 | 38.79 |
| 02:02 ET | 300 | 38.76 |
| 02:04 ET | 400 | 38.79 |
| 02:06 ET | 400 | 38.79 |
| 02:08 ET | 1658 | 38.615 |
| 02:09 ET | 2400 | 38.695 |
| 02:11 ET | 200 | 38.695 |
| 02:13 ET | 200 | 38.69 |
| 02:15 ET | 2008 | 38.595 |
| 02:18 ET | 400 | 38.68 |
| 02:22 ET | 1100 | 38.7 |
| 02:24 ET | 500 | 38.74 |
| 02:26 ET | 697 | 38.67 |
| 02:27 ET | 574 | 38.83 |
| 02:29 ET | 673 | 38.7 |
| 02:31 ET | 260 | 38.77 |
| 02:33 ET | 300 | 38.79 |
| 02:36 ET | 300 | 38.81 |
| 02:38 ET | 1342 | 38.79 |
| 02:40 ET | 2588 | 38.765 |
| 02:42 ET | 300 | 38.76 |
| 02:44 ET | 200 | 38.755 |
| 02:45 ET | 600 | 38.79 |
| 02:47 ET | 200 | 38.83 |
| 02:49 ET | 8061 | 38.845 |
| 02:51 ET | 1084 | 38.81 |
| 02:54 ET | 341 | 38.845 |
| 02:56 ET | 400 | 38.84 |
| 02:58 ET | 536 | 38.89 |
| 03:00 ET | 500 | 38.92 |
| 03:02 ET | 329 | 38.94 |
| 03:03 ET | 825 | 38.96 |
| 03:05 ET | 400 | 38.92 |
| 03:07 ET | 400 | 39.03 |
| 03:09 ET | 1116 | 38.96 |
| 03:12 ET | 300 | 39.02 |
| 03:16 ET | 8158 | 39.03 |
| 03:18 ET | 29425 | 39.005 |
| 03:20 ET | 1700 | 39.1 |
| 03:21 ET | 400 | 39.05 |
| 03:23 ET | 8764 | 39 |
| 03:25 ET | 7525 | 39 |
| 03:27 ET | 2332 | 39.1 |
| 03:34 ET | 2841 | 39.18 |
| 03:36 ET | 1811 | 39.29 |
| 03:38 ET | 600 | 39.36 |
| 03:39 ET | 8771 | 39.065 |
| 03:41 ET | 4917 | 39.07 |
| 03:43 ET | 700 | 39.01 |
| 03:45 ET | 1422 | 39.07 |
| 03:48 ET | 500 | 39.045 |
| 03:50 ET | 1168 | 39.1 |
| 03:52 ET | 3770 | 39.09 |
| 03:54 ET | 2040 | 39.115 |
| 03:56 ET | 2947 | 39.015 |
| 03:57 ET | 8651 | 38.92 |
| 03:59 ET | 11980 | 39.04 |
May 28, 2024
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.4x | --- |
Biohaven Ltd | 2.9B | -5.2x | --- |
Dyne Therapeutics Inc | 3.0B | -7.9x | --- |
SpringWorks Therapeutics Inc | 3.0B | -8.3x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Apogee Therapeutics Inc | 2.6B | -22.7x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
